Introduction
Clostridium dif®cile is a Gram positive, spore forming anaerobe commonly implicated in antibiotic associated diarrhoea. It causes a spectrum of illness, ranging from mild abdominal discomfort to fulminant pseudomembranous colitis. C. dif®cile infection accounts for a signi®cant increase in hospital status and resource utilization, one recent estimate attributing more than US$1.1 billion in health care costs in the US per annum [1] to its management. The incidence of C. dif®cile diarrhoea may be rising. In one US series, during 2000, the incidence increased from 0.68% to 1.2% of hospitalized patients, of whom 3.2% developed life threatening symptoms [2] . The cause of the increase is not clear, but the authors did not believe that improved recognition of the disease contributed signi®cantly. Increasing morbidity, however, may not be matched by rising mortality; at 3 months and 1 year there was no excess mortality attributable to C. dif®cile after adjustment for comorbidity and age [1] , suggesting that C. dif®cile is a marker but not a cause of increased risk of dying.
Colitis is not the only consequence of C. dif®cile infection. Liver abscess [3] , bacteraemia and sepsis syndrome, splenic and pancreatic abscesses, peritonitis, small bowel enteritis [4] , bone and joint infections (including prostheses) have all been described [5 . ,6]. More controversially associations with reactive arthritis, encephalopathy and even sudden infant death syndrome [7] have been made, but with less evidence [5 . ,6] . The signi®cance of extraintestinal C. dif®cile infection should be viewed with caution, since a series of all cases over a 10-year period failed to attribute morbidity to C. dif®cile alone, most cases being polymicrobial and involving non-toxigenic C. dif®cile strains, and without prior antibiotic exposure or associated diarrhoea [6] . Predisposing factors for the development of C. dif®cile diarrhoea have been studied extensively. One study observed 7% of patients on courses of myelosuppressive chemotherapy to have C. dif®cile diarrhoea [8 . ]. The association between antineoplastic chemotherapy and C. dif®cile has two principal aspects: ®rstly the direct in¯ammatory effects of cytotoxic agents on the gut, potentially clouding the diagnosis [9 . ], and secondly, neutropenia [8 . ], especially in the setting of broad-spectrum neutropenic sepsis antibiotic regimens.
Predisposing antibiotics
The main predisposing factor for C. dif®cile diarrhoea is antibiotic therapy, notably with cephalosporins, clindamycin, and broad spectrum penicillins [10 . ]. The roles of the new quinolones and antibiotic duration, including short-term prophylaxis, have been investigated recently. Duration of antimicrobial therapy is an important factor in assessing the risk of C. dif®cile diarrhoea. A large (n = 2462) prospective study of patients in ®ve Swedish hospitals demonstrated that patients treated for fewer than 3 days had a signi®cantly lower incidence of C. dif®cile infection than those receiving longer courses of antibiotic therapy [10 . ]. A smaller retrospective study of prophylaxis following clean cardiovascular surgery failed to demonstrate an increase in the rare complication of C. dif®cile diarrhoea when extended vancomycin or cefazolin prophylaxis was used. (77 versus 31 hours) [11] .
The antimicrobial agents most frequently associated with C. dif®cile are those which have a broad antibacterial spectrum, with little inherent activity against C. dif®cile. Quinolone resistance in C. dif®cile, however, occurred in over 30% of strains in a recent Spanish series [12 . ]. Macrolides, especially clarithromycin, have been proposed to be risk factors in the development of C. dif®cile diarrhoea. However the unusual situation of hospitalized patients being prescribed clarithromycin alone means that confounding factors are dif®cult to exclude [13] . In a single case report, C. dif®cile diarrhoea followed a commonly used Helicobacter pylori eradication therapy including clarithromycin as the only antibiotic [14] .
So far, there has been little evidence that quinolones induce C. dif®cile diarrhoea, perhaps due to the poor antianaerobic activity of the older forms. Interestingly, six of nine patients with C. dif®cile infection over 6 months in a nursing home had previously been given levo¯oxacin, in three cases in combination with another antibiotic [15 . ]. Recent evidence has incriminated cipro¯oxacin as a possible predisposing cause of C. dif®cile infection. In a retrospective case±control study which identifed 27 patients over 3 months in a 300-bed tertiary care hospital, prior exposure to cephalosporins and use of cipro¯oxacin were found to be signi®cant only on a multivariate analysis [16] .
Bacterial resistance to quinolones is mediated by mutations in gyrA and gyrB (the quinolone resistance determining regions of DNA gyrase) and parC and parE (for subunits A and B of DNA topoisomerase IV). In general, quinolone resistance in Gram negative bacteria is mediated by mutations in gyrA and gyrB, whereas in Gram positives aberrant parC and parE are commonly implicated. C. dif®cile resistance to moxi¯oxacin has been found to be mediated by alterations in DNA gyrase via a gyrA mutation. Drug ef¯ux mechanisms may also contribute to the resistant phenotype [17] .
Epidemiology
There is increasing evidence for clonal spread of C. dif®cile, and there have been several advances in the methods used for detection of related strains. The discriminatory technique of pulse ®eld gel electrophoresis, with its unwieldy and time consuming protocol, has been beset by problems, with DNA degradation rendering some C. dif®cile isolates untypable including the UK epidemic strain. Polymerase chain reaction (PCR) ribotyping is technically easier and gives results in a shorter time, but is less likely to differentiate between strains [18] . Toxinotyping, based on PCR-restriction fragment length polymorphism, analyses a 19 kb region encompassing the C. dif®cile pathogenicity locus and is an alternative to ribotyping, with good correlation in toxigenic strains [19 . ]. Ampli®ed fragment length polymorphism has been shown to be a rapid reliable method, yielding high resolution and reproducible DNA ®ngerprinting patterns within 24 h, compared with 3 days using pulse ®eld gel electrophoresis. DNA restriction fragments are made by digestion with EcoR1 and Mse1, then ampli®ed using EcoR1 and Mse1 primers [19 . ,20 . . ].
The demonstration of clonal spread of C. dif®cile was often not highlighted in these methodology papers, but clonal spread has been demonstrated both in the outbreak setting and in the investigation of endogenous environmental strains. Some clones have been widely disseminated. For example a toxin A7, B+ strain isolated during an outbreak in Poland was shown to be indistinguishable from a Japanese reference strain [21 . ]. Such emerging strains may share biologically advantageous characteristics, which require further investigation. In a 6-month survey of the epidemiology of strains prevalent in a newly opened elderly care ward, random ampli®ed polymorphic DNA and RNA template speci-®c-PCR ®ngerprinting were used to demonstrate that of over 200 isolates from C. dif®cile diarrhoea patients and the ward environment, there were only six distinct types [22] . A non-UK endemic strain caused a cluster of six cases, and this was isolated in the environment only after the sixth symptomatic patient was noted, implying patient to patient, or staff to patient spread being the major routes [23] . There may also be an association between the level of environmental contamination and the number of cases, but this may be either a cause or consequence of diarrhoea [22] 
Diagnosis/toxin assays
Differentiating between uncomplicated diarrhoea and pseudomembranous colitis can be dif®cult clinically, but has implications for treatment and prognosis. Recent studies indicate that an increased leucocyte count or abnormal computed tomography results may be more discriminating than colonoscopy or clinical examination alone [2,26 . ]. There have been few signi®cant recent developments in the laboratory diagnosis of C. dif®cile diarrhoea. Reports have concentrated upon comparing simple rapid detection techniques with the gold standards of bacterial culture and particular cell culture based cytotoxin assays [27] . A rapid electroimmunoassay for simultaneous detection of C. dif®cile toxin A and common antigen has been developed. A C. dif®cile common antigen test had a 100% negative predictive value, and the toxin A test had a 100% positive predictive value. Of 102 samples tested, ®ve were positive by both tests, 23 were common antigen positive, toxin A negative, of which 10 were found to be toxin positive by cell culture assay and two more by PCR. For those samples found to be common antigen positive and toxin A negative, a standard cytotoxin assay is suggested [28 . . ]. The advantage is the speed of detection: use of this 15-min assay potentially avoids the prolonged isolation of patients whose specimens are common antigen negative. Of single tests seeking toxin only, by rapid same day immunoassay, none were found to be as sensitive as a cytotoxin assay [27,29±31] .
The signi®cance of toxin A7, B+ strains has been debated recently, but the weight of evidence now suggests that toxin A detection alone is insuf®cient for the laboratory diagnosis of C. dif®cile diarrhoea. In addition to reports of clonal spread of toxin A7, B+ strains, two recent case reports of patients with severe pseudomembranous colitis, one of whom died, caused by strains not detected by toxin A immunoassays [32,33 . ] strongly support this assertion.
Laboratory diagnosis is further complicated by the issue of`second look cytotoxicity'. A Spanish study demonstrated that an increase of 15% in the detection rate might be achieved by demonstrating cytotoxin production by cultured C dif®cile as well as directly from faecal specimens. It has been proposed that toxins may degrade and become inactive in stool samples that are inadequately transported and processed. Of 1691 C. dif®cile cultures yielding toxin B, 1437 gave a direct positive faecal cytotoxin result, whereas 254 (15%) were only positive after`second look' cell culture assay. The affected patients all had diarrhoea, no other enteric pathogen isolated, and responded to anticlostridial therapy. This method is however, time consuming, taking at least 3 days to produce a result [34 . ]. Repeat toxin testing on follow-up specimens in patients who remain symptomatic may be more cost/resource effective.
Pathogenicity
Recent research has improved the understanding of C. dif®cile pathogenicity at a cellular level. Notably, several papers have investigated the role of adhesion. An assay based on¯ow cytometry has been developed for the detection of adherence to human colonic and small intestinal cells [35] . The heat shock protein GroEL has been shown to have a role in adherance [36] . Another proteinaceous surface moiety, Cwp66, shown to improve adherence to cultured cells following heat shock, has homology with adhesins and autolysins of other bacteria. Antibodies to Cwp66 were partially inhibitory in cell binding studies, con®rming Cwp66 to be an adhesin [37 . ]. The autolytic properties of Cwp66 in C. dif®cile are also under investigation. The highly conserved [38] agellar proteins FliC and FliD also have an important role in gut colonization and adherence, possibly in bacterial attachment to speci®c cell receptors [39] .
Toxins A (sometimes called enterotoxin) and B (cytotoxin) are perhaps the best studied C. dif®cile virulence determinants, causing cell death by disrupting the actin cytoskeleton, inducing the production of in¯ammatory interleukins and tumour necrosis factor [40 . . ], and disrupting epithelial cell tight junction proteins [41] . Toxins A and B lack a signal peptide to facilitate their release. A 501-base pair open reading frame of previously unknown origin has been discovered between the genes encoding the toxins on the pathogenicity locus of C. dif®cile. The predicted amino acid sequence has structural similarities to holins, which are bacteriophage proteins, which cause lysis of the host cell in order to release progeny phages. It has been proposed that these holin like proteins allow release of the toxins to the extracellular environment, and perhaps have a role in sporulation [42 . ].
Treatment
The mainstay of treatment of C. dif®cile remains metronidazole. Oral metronidazole is effective in neutropenic patients [8 . ]. Faecal bactericidal levels can be achieved when metronidazole is given by the intravenous route, and is a viable option when the oral route is precluded. It is dif®cult to compare the ef®cacy of the intravenous route with the oral, since there is often a selection bias: the more severely ill patients are those who cannot tolerate oral administration [43] . A formal randomized trial is needed before a conclusion can be drawn; and in practice for patients with severe symptoms who cannot receive oral therapy, a combination of intravenous vancomycin and intravenous metronidazole should be considered. A worrying development is the ®rst detection in the UK of metronidazole resistance, in a non-toxigenic C. dif®cile strain [44 . ]. It is not yet clear whether resistance can be transferred to toxigenic strains. Although the minimum inhibitory concentration of this strain was close to the breakpoint, in the setting of colitis the faecal concentration of metronidazole is usually higher than the minimum inhibitory concentration reported in this case.
Vancomycin administered via enteral tubes has been successful in recent reports, when the oral route is unavailable. It has been given as adjunctive therapy in severe C. dif®cile colitis with toxic megacolon alongside decompressive therapy [45] , and when the colon had been previously diverted [46] . Probiotics, including Saccharomyces spp. and Lactobacillus spp., have previously been investigated in a number of small studies with mixed results. A large randomized placebo-controlled trial of Lactobacillus GG for the prevention of antibiotic associated diarrhoea showed no decrease in the rate of diarrhoea or of C. dif®cile infection in patients receiving biotherapy [47 . ]. The non-pathogenic yeast Saccharomyces boulardii is used in some cases of refractory C. dif®cile diarrhoea. The immune response to C. dif®cile toxins is important in the pathogenesis of colitis. It has been shown recently that in a mouse model, intestinal immunoglobulin A antitoxin A secretion is stimulated by S. boulardii following oral immunization, offering one possible explanation regarding its ef®cacy [48 . ].
A high molecular weight toxin binding polymer, GT160-246, is undergoing investigation for treatment of C. dif®cile diarrhoea. It has no direct antimicrobial activity, but binds toxins A and B, and has been shown to protect C. dif®cile infected hamsters from mortality, although not from initial development of colitis [49 . . ]. The treatment has been shown to be well tolerated in phase I trials, and offers a promising alternative to current therapies.
It has been shown that a serum antibody rise to toxin A during an initial infection with C. dif®cile protects against recurrence [50 . . ], and trials are now in progress to investigate both active and passive immunization. A toxoid vaccine has been shown to be safe and immunogenic in healthy volunteers, when measured by both increasing serum immunoglobulin G and faecal immunoglobulin A levels [51 . . ]. The authors are optimistic about the eventual use of a vaccination for immune stimulation in both the treatment and prevention of C. dif®cile infection in high risk patients [51 . . ]. It
is not yet clear whether it will be effective in the target population, since severe infection in the elderly may be attributable to a compromised immune response. These moves towards non-antibiotic based treatments/prevention options for C. dif®cile infection are welcome considering the iatrogenic antimicrobial causes of the disease.
Conclusion
C. dif®cile remains an important nosocomial cause of morbidity and mortality. During the past year there have been signi®cant advances in the understanding of the microbiology and pathogenesis of C. dif®cile infection. However, despite improving techniques for diagnosis, high recurrence rates following treatment and possible antibiotic resistance issues necessitate the development of alternative therapeutic strategies. Encouraging research in the areas of vaccine discovery and toxin binding agents may hold promise for the future. Insights into the epidemiology of C. dif®cile may lead to improved infection control strategies, which despite the advancement of knowledge continue to be the main preventative strategy for this important infection.
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